Icecure Medical is trading at $1.60, down -5.48%, with no clear company-specific catalyst identified for the October 2 decline.
- IceCure Medical’s investor-relations page lists September 10’s China regulatory approval announcement as its latest news; it predates the decline.
- Major U.S. indexes were higher while healthcare was lower, but neither establishes a direct cause for the stock’s decline.
- No trading-volume details were provided.